Voisard Asset Management Group Inc. Acquires 205 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Voisard Asset Management Group Inc. lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 17.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,355 shares of the biotechnology company’s stock after buying an additional 205 shares during the period. Voisard Asset Management Group Inc.’s holdings in BioMarin Pharmaceutical were worth $95,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Primecap Management Co. CA lifted its stake in shares of BioMarin Pharmaceutical by 0.4% in the second quarter. Primecap Management Co. CA now owns 18,790,085 shares of the biotechnology company’s stock worth $1,546,988,000 after buying an additional 76,190 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of BioMarin Pharmaceutical by 0.4% in the first quarter. Vanguard Group Inc. now owns 18,117,108 shares of the biotechnology company’s stock worth $1,582,348,000 after buying an additional 67,046 shares in the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of BioMarin Pharmaceutical by 4.4% in the second quarter. Avoro Capital Advisors LLC now owns 4,557,416 shares of the biotechnology company’s stock worth $375,212,000 after buying an additional 192,416 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of BioMarin Pharmaceutical by 38.9% in the second quarter. Dimensional Fund Advisors LP now owns 1,034,457 shares of the biotechnology company’s stock worth $85,178,000 after buying an additional 289,953 shares in the last quarter. Finally, DNB Asset Management AS lifted its stake in shares of BioMarin Pharmaceutical by 17.7% in the second quarter. DNB Asset Management AS now owns 1,021,054 shares of the biotechnology company’s stock worth $84,063,000 after buying an additional 153,867 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN opened at $66.68 on Thursday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.95 and a current ratio of 3.05. The firm has a fifty day moving average price of $76.08 and a 200 day moving average price of $80.94. BioMarin Pharmaceutical Inc. has a fifty-two week low of $65.78 and a fifty-two week high of $99.56. The firm has a market cap of $12.66 billion, a price-to-earnings ratio of 62.32, a P/E/G ratio of 0.81 and a beta of 0.31.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). BioMarin Pharmaceutical had a return on equity of 6.91% and a net margin of 9.91%. The company had revenue of $746.00 million for the quarter, compared to the consensus estimate of $703.37 million. During the same quarter in the prior year, the company posted $0.26 EPS. BioMarin Pharmaceutical’s revenue was up 28.4% compared to the same quarter last year. As a group, sell-side analysts expect that BioMarin Pharmaceutical Inc. will post 2.39 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on BMRN shares. Truist Financial dropped their target price on shares of BioMarin Pharmaceutical from $118.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday, September 17th. Citigroup decreased their price objective on shares of BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating for the company in a report on Wednesday. Wells Fargo & Company decreased their price objective on shares of BioMarin Pharmaceutical from $115.00 to $90.00 and set an “overweight” rating for the company in a report on Tuesday, September 17th. TD Cowen decreased their price objective on shares of BioMarin Pharmaceutical from $125.00 to $120.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Finally, Stifel Nicolaus decreased their price objective on shares of BioMarin Pharmaceutical from $115.00 to $87.00 and set a “buy” rating for the company in a report on Tuesday, September 17th. Eight analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus price target of $93.67.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.